PDCD1 and melanoma: The presence of high clonal neoantigen burden in tumours with low neoantigen intra-tumour heterogeneity was furthermore shown to be associated with longer progression free survival in anti-PD-1 treated NSCLC and also associated with longer overall survival in anti-CTLA4 treated melanoma [21].